In vitro, in vivo, and in silico approaches for evaluating the preclinical DMPK profiles of ammoxetine, a novel chiral serotonin and norepinephrine reuptake inhibitor
This study presents encouraging DMPK profiles of ammoxetine, backing its potential as a candidate compound for future clinical assessments.
Authors
- Yuexin Li (ORCID: https://orcid.org/0000-0001-8525-2853)
- Xiuqing Zhu
- Jinglai Li
- Zhenqing Zhang (ORCID: https://orcid.org/0000-0003-2490-5026)
- Yunxia Zhang (ORCID: https://orcid.org/0000-0002-5637-6782)
- Huan Luo
Institutions
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-07
- DOI
- https://doi.org/10.3389/fphar.2024.1486856
- Citations
- 3
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 1.34
Funders
- Guangdong Provincial Hospital of Traditional Chinese Medicine